This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $25.64 in the latest trading session, marking a -1.99% move from the prior day.
Anika (ANIK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.
Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.
Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.77, marking a +1.38% move from the previous day.
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $26.57 in the latest trading session, marking a +0.15% move from the prior day.
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
by Zacks Equity Research
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
by Zacks Equity Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $28.98 in the latest trading session, marking a +0.98% move from the prior day.
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $26.47, marking a -0.45% move from the previous day.
Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
by Zacks Equity Research
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication
by Zacks Equity Research
The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
by Zacks Equity Research
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
Angion (ANGN) Down on Merger Agreement With Private Biotech
by Zacks Equity Research
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.